Advisors Asset Management Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 38,576 shares of the company's stock after purchasing an additional 4,549 shares during the quarter. Advisors Asset Management Inc.'s holdings in Neurocrine Biosciences were worth $4,445,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Neurocrine Biosciences by 0.8% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock worth $1,574,000 after purchasing an additional 90 shares during the last quarter. Fifth Third Bancorp raised its position in Neurocrine Biosciences by 14.7% in the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company's stock worth $99,000 after buying an additional 92 shares during the last quarter. Total Clarity Wealth Management Inc. raised its position in Neurocrine Biosciences by 4.3% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock worth $335,000 after buying an additional 100 shares during the last quarter. Commerce Bank lifted its stake in Neurocrine Biosciences by 2.6% during the 3rd quarter. Commerce Bank now owns 4,199 shares of the company's stock valued at $484,000 after acquiring an additional 108 shares during the period. Finally, Caprock Group LLC boosted its holdings in shares of Neurocrine Biosciences by 7.0% during the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company's stock valued at $230,000 after acquiring an additional 109 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.
Several research firms have recently weighed in on NBIX. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a report on Friday, August 2nd. StockNews.com cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Barclays cut their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a report on Monday, September 9th. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group boosted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research note on Monday, August 19th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $163.91.
Check Out Our Latest Stock Analysis on NBIX
NASDAQ NBIX opened at $125.65 on Friday. The business has a 50-day moving average price of $118.55 and a 200-day moving average price of $132.13. The firm has a market cap of $12.72 billion, a price-to-earnings ratio of 33.69 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $110.52 and a twelve month high of $157.98.
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.